AASLD guidelines for the treatment of hepatocellular carcinoma

被引：3334

作者：

Heimbach, Julie K. ^{[1
]}

Kulik, Laura M. ^{[2
]}

Finn, Richard S. ^{[3
,4
]}

Sirlin, Claude B. ^{[5
]}

Abecassis, Michael M. ^{[6
]}

Roberts, Lewis R. ^{[7
]}

Zhu, Andrew X. ^{[8
]}

Murad, M. Hassan ^{[9
]}

Marrero, Jorge A. ^{[10
]}

机构：

[1] Mayo Clin, Div Transplant Surg, William J von Liebig Transplant Ctr, Charlton 10 200 First St SW, Rochester, MN 55905 USA

[2] Northwestern Univ, Dept Med, Div Gastroenterol & Hepatol, Chicago, IL 60611 USA

[3] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol & Oncol, Dept Med, Los Angeles, CA 90095 USA

[4] Univ Calif Los Angeles, Santa Monica Geffen Sch Med, Los Angeles, CA USA

[5] Univ Calif San Diego, Dept Radiol, Liver Imaging Grp, San Diego, CA 92103 USA

[6] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[7] Mayo Clin, Div Gastroenterol & Hepatol, Charlton 10 200 First St SW, Rochester, MN 55905 USA

[8] Harvard Med Sch, Ctr Canc, Massachusetts Gen Hosp, Boston, MA USA

[9] Mayo Clin, Evidence Based Practice Ctr, Charlton 10 200 First St SW, Rochester, MN 55905 USA

[10] UT Southwestern Med Ctr, Digest & Liver Dis Div, Dept Internal Med, Dallas, TX USA

来源：

HEPATOLOGY | 2018年 / 67卷 / 01期

关键词：

CONTRAST-ENHANCED ULTRASOUND; RANDOMIZED CONTROLLED-TRIAL; TRANSARTERIAL LIPIODOL CHEMOEMBOLIZATION; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; VEIN TUMOR THROMBOSIS; NODULES; 20; MM; LIVER-TRANSPLANTATION; RADIOFREQUENCY ABLATION; PARTIAL-HEPATECTOMY; RISK-FACTORS;

D O I：

10.1002/hep.29086

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

[No abstract available]

引用

页码：358 / 380

页数：23

共 99 条

[1]

Abdel-Rahman OM, 2016, COCHRANE DB SYST REV, P1

[2] Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial [J].

Akamatsu, M ;

Yoshida, H ;

Obi, S ;

Sato, S ;

Koike, Y ;

Fujishima, T ;

Tateishi, R ;

Imamura, M ;

Hamamura, K ;

Teratani, T ;

Shiina, S ;

Ishikawa, T ;

Omata, M .

LIVER INTERNATIONAL, 2004, 24 (06) :625-630

[3]

[Anonymous], 2016, LIV IM REP DAT SYST

[4]

Atkins D, 2004, BMJ-BRIT MED J, V328, P1490

[5]

BEAUGRAND M, 1993, HEPATOLOGY, V18, pA58

[6] Liver transplantation for hepatocellular carcinoma [J].

Bismuth, H ;

Majno, PE ;

Adam, R .

SEMINARS IN LIVER DISEASE, 1999, 19 (03) :311-322

[7] Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma:: Results of a randomized, controlled trial in a single institution [J].

Bruix, J ;

Llovet, JM ;

Castells, A ;

Montañá, X ;

Brú, C ;

Ayuso, MD ;

Vilana, R ;

Rodés, J .

HEPATOLOGY, 1998, 27 (06) :1578-1583

[8] Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial [J].

Bruix, Jordi ;

Takayama, Tadatoshi ;

Mazzaferro, Vincenzo ;

Chau, Gar-Yang ;

Yang, Jiamei ;

Kudo, Masatoshi ;

Cai, Jianqiang ;

Poon, Ronnie T. ;

Han, Kwang-Hyub ;

Tak, Won Young ;

Lee, Han Chu ;

Song, Tianqiang ;

Roayaie, Sasan ;

Bolondi, Luigi ;

Lee, Kwan Sik ;

Makuuchi, Masatoshi ;

Souza, Fabricio ;

Le Berre, Marie-Aude ;

Meinhardt, Gerold ;

Llovet, Josep M. .

LANCET ONCOLOGY, 2015, 16 (13) :1344-1354

[9] Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial [J].

Bruix, Jordi ;

Raoul, Jean-Luc ;

Sherman, Morris ;

Mazzaferro, Vincenzo ;

Bolondi, Luigi ;

Craxi, Antonio ;

Galle, Peter R. ;

Santoro, Armando ;

Beaugrand, Michel ;

Sangiovanni, Angelo ;

Porta, Camillo ;

Gerken, Guido ;

Marrero, Jorge A. ;

Nadel, Andrea ;

Shan, Michael ;

Moscovici, Marius ;

Voliotis, Dimitris ;

Llovet, Josep M. .

JOURNAL OF HEPATOLOGY, 2012, 57 (04) :821-829

[10] Management of Hepatocellular Carcinoma: An Update [J].

Bruix, Jordi ;

Sherman, Morris .

HEPATOLOGY, 2011, 53 (03) :1020-1022

← 1 2 3 4 5 6 7 8 9 10 →